27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Understanding the lifetime risk of dementia can inform public health planning and improve patient engagement in prevention. 1 key finding →
Design: cohort Participants: 15,043 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
After multivariable adjustment, patients showed an odds ratio (OR) 1·61 (95% CI 0·80-3·25) for scale 4 versus scale 3 and 4·60 (1·85-11·48) for scale 5-6 versus scale 3 for diffusion impairment; OR 0·88 (0·66-1·17) for scale 4 versus scale 3 and OR 1·77 (1·05-2·97) for scale 5-6 versus scale 3 for anxiety or depression, and OR 0·74 (0·58-0·96) for scale 4 versus scale 3 and 2·69 (1·46-4·96) for scale 5-6 versus scale 3 for fatigue or muscle weakness. 2 key findings →
Design: cohort study Participants: 94 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We tested the trained model using five other studies, three of which used PET as a biomarker of significant amyloid β burden (testing the deep learning model between amyloid β positive vs amyloid β negative). 2 key findings →
Design: case-control study Participants: 648 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We conducted a systematic review of research in artificial intelligence (AI) for retinal fundus photographic images. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
To test whether cerebrospinal fluid (CSF) growth-associated protein 43 (GAP-43) concentration is elevated in Alzheimer's disease (AD) dementia and its associations with other hallmarks of AD, we examined the CSF GAP-43 measurements of 787 participants (245 cognitively normal (CN), 415 individuals with mild cognitive impairment (MCI) and 127 individuals with AD dementia) from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study. 4 key findings →
Design: longitudinal study Participants: 787 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Genetic risk for AD does not modify the association between hypertension and dementia. 4 key findings →
Design: cohort Participants: 11,597 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Triggering receptor expressed on myeloid cells-2 (TREM2) and progranulin (PGRN) are critical regulators of microglia activation and can be detected in cerebrospinal fluid (CSF). 4 key findings →
Design: longitudinal study Participants: 65 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Aging and age-related diseases share convergent pathways at the proteome level. 1 key finding →
Participants: 43,616 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
It has been well established that the TMEM106B gene rs1990622 variant was a frontotemporal dementia (FTD) risk factor. 4 key findings →
Participants: 314,278 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
For detecting AD-dementia, the ensemble model achieved the area under the receiver operating characteristic curve (AUROC) of 0.943 (95% confidence interval, 0.906-0.980), 0.786 (95% confidence interval, 0.673-0.899), and 0.795 (95% confidence interval, 0.716-0.874) in the internal validation, External-1, and External-2, respectively. 4 key findings →
Design: case-control study Participants: 190 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The estimated total annual costs of dementia in China increased from 0.9 billion United States dollars (US$) in 1990 to US$ 47.2 billion in 2010 and were predicted to reach US$ 69.0 billion in 2020 and US$ 114.2 billion in 2030. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Spatial transcriptomics enables the simultaneous measurement of morphological features and transcriptional profiles of the same cells or regions in tissues. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Polygenic risk scores (PRSs) predict an individual's genetic risk for complex diseases, yet their utility in elucidating disease biology remains limited. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
• Limited evidence links air pollution-lifestyle interplay to cardiovascular disease. • Study includes over 5.8 million participants from arid Northwestern China. • Air pollution in dust-prone areas is linked to cardiovascular disease. • Exercise is crucial in reducing the risk of cardiovascular disease from air pollution. • Air pollution and unhealthy lifestyles jointly heighten cardiovascular risk. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With the publication in 2015 of the consensus statement by the perfusion study group of the International Society for Magnetic Resonance in Medicine (ISMRM) and the EU-COST action 'ASL in dementia' on the implementation of arterial spin labelling MRI (ASL) in a clinical setting, the development of ASL can be considered to have become mature and ready for clinical prime-time. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dementia, a chronic and progressive cognitive declination of brain function caused by disease or impairment, is becoming more prevalent due to the aging population. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among 389,314 participants, CKM stages were distributed as follows: stage 0 (10.0%), stage 1 (8.0%), stage 2 (57.6%), stage 3 (17.9%), and stage 4 (6.5%). 5 key findings →
Participants: 389,314 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Flexible and wearable electronics are attracting surging attention due to their potential applications in human health monitoring and precision therapies. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundElectroencephalogram (EEG) is a promising, non-invasive method for identifying the presence of Alzheimer's disease (AD) by recognizing specific brain activity patterns associated with the disease. 3 key findings →
Participants: 431 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
MicroRNA (miR) dysregulation is found in Alzheimer disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
AD patients exhibited a significant reduction in the water exchange rates across the BBB, whereas DLB patients showed a significant increase in BBB permeability to contrast agent. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Emerging evidence indicates that globus pallidus (GP) function can be modulated by orexin-A in movement disorders, while its role in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) remains unclear. 4 key findings →
Participants: 25 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A total of 156 patients were clinically diagnosed with dementia based on the 2011 NIA-AA criteria, regardless of specific disease etiology, and all exhibited significant brain atrophy on anatomical magnetic resonance imaging (MRI), indicating neuronal injury (N+). 5 key findings →
Participants: 156 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Diabetic-related cognitive dysfunction, especially mild cognitive impairment (MCI), is a serious complication of type 2 diabetes mellitus (T2DM). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
-glycans found at the N304 site of lecanemab of the heavy chain. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →